news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

[Dahe Financial Cube reporter Wang Leibin] According to the latest news released by the Chinese Center for Disease Control and Prevention, the new coronavirus infection rate in my country has shown a clear upward trend in recent times.

The World Health Organization also said that at least 40 athletes were infected with the new coronavirus and other respiratory disease pathogens during the Paris Olympics. The international community should pay attention to the abnormal increase in new coronavirus infections in the summer and recommends vaccination for the most at-risk groups with the new coronavirus vaccine.

On August 13, in response to the rising trend of COVID-19 infection rates, a reporter from Dahe Financial Cube interviewed the relevant person in charge of Henan Zhenzheng Biotechnology Co., Ltd. (hereinafter referred to as "Zhenzheng Biotechnology"), the manufacturer of the country's first COVID-19 therapeutic drug, Azvudine.

The person in charge said that recently, the infection rate of the new coronavirus has shown a clear upward trend. As the first domestically produced oral new coronavirus drug approved in China, Real Bio has clearly felt the increase in market demand for Azvudine since July. The current reserves of Azvudine are sufficient to fully meet market demand. The company is always paying attention to the new coronavirus infection dynamics and adjusting production capacity in a timely manner according to market demand.

As the first domestically produced oral COVID-19 drug included in the national medical insurance catalogue, Azvudine has been listed on the medical insurance network in 31 provinces, autonomous regions, and municipalities across the country. The medical insurance payment price is 175 yuan per bottle, covering more than 50,000 medical institutions across the country, and can effectively meet the basic medication needs of the people.